AD, Data Operations & Reporting

Albireo Pharma Overview:

Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo has deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs.

The company’s first commercial launch will be Odevixibat, which is a potent and selective inhibitor of the ileal bile acid transporter (IBAT), sometimes referred to as the apical sodium dependent bile acid transporter (ASBT), that has minimal systemic exposure at therapeutic doses and acts locally in the gut.

Odevixibat has the potential to become the first approved pharmacologic treatment for patients with PFIC. The Company intends to complete regulatory filings in the EU and in the U.S. no later than early 2021, in anticipation of potential regulatory approval, issuance of a rare pediatric disease priority review voucher and launch in the second half of 2021, if approved. The Company also plans to initiate a pivotal Phase 3 trial of odevixibat in Alagille syndrome by the end of 2020, and to continue enrolling patients in the BOLD pivotal Phase 3 trial of odevixibat in biliary atresia. Albireo continues to progress its pipeline and expects to complete IND-enabling studies for a new preclinical candidate this year.

The U.S. Food and Drug Administration (FDA) has granted to the Odevixibat PFIC program or elements of its fast track, rare pediatric disease and orphan drug designations. The European Medicines Agency (EMA) has granted Odevixibat orphan designation, as well as access to the Priority Medicine’s (PRIME) scheme for the treatment of PFIC. Its Pediatric Committee has agreed to Albireo's Odevixibat Pediatric Investigation Plan for PFIC. Both FDA and EMA also have granted orphan drug designation to Odevixibat for the treatment of Alagille syndrome and primary biliary cholangitis. Albireo will commercialize Odevixibat in the US, Europe & Canada and is pursuing potential partners in remaining regions.

We have a unique opportunity for a high-performing commercial Data Operations & Reporting professional to help with our first commercial launch, as well as potential future indications. Based in Boston, this role will report to the Senior Director of Commercial Analytics.

Core responsibilities:

  • Define, create and produce management and field reporting dashboards
  • SP data management (scorecarding, invoice, problem resolution)
  • Serve as data steward for all commercial data (HCP and payer mastering)

Additional responsibilities:

  • Liaison with IT and external data vendors (CDE provider, MMIT, payer mastering) from a commercial standpoint
  • Incentive comp calculation


  • Minimum 5 years of biopharma forecasting & analytics experience
  • Excellent project management ability
  • Superior Excel modeling ability, and high level of ability in PowerPoint
  • Ability to communicate data via clear visuals
  • High attention to detail, diligence and reliability
  • High empathy and strong interpersonal skills
  • Ability to work both independently and collaboratively with a diverse team
  • Ability to work quickly and flexibly with resource constraints
  • High integrity and commitment to working within full legal/regulatory compliance
  • Desire to be part of a small, dynamic, mission-driven company
  • Bachelor’s degree

Preferred qualifications:

  • Product launch experience
  • U.S. and global experience
  • Rare disease experience
  • Hepatology or gastroenterology experience
  • Experience in a small, pre-launch company
  • Advanced degree in a relevant discipline (marketing, quantitative analysis, etc.)


Full time
Salary Range
$57,000.00 - 91,000.00
per Year
Salary range estimated by
Boston, MA 02109, US